Treatment of central precocious puberty.
This chapter describes several aspects of the management of treatment in girls and boys with central precocious puberty. Although there is some controversy about the indication for gonadotrophin releasing hormone (GnRH) agonist treatment in the literature, a list of clear indications is presented and monitoring requirements for treatment are discussed with reference to the pertinent literature. The development of clinical, psychological, hormonal, sonographical and auxological parameters that can be expected during GnRH agonist treatment is described in detail. In view of the scant evidence-based knowledge, we review the final outcome of patients treated with GnRH agonists with respect to reversibility of hormonal suppression, reproductive function, final height and side effects. The data published so far show that GnRH agonist treatment using the modern depot preparations is not only convenient but also safe, with relatively minor side effects. The outcome in terms of final height is favourable in the majority of patients.
Partsch
Carl-Joachim
CJ
Division of Paediatric Endocrinology, Department of Paediatrics, Kinderklink, Christian Albrechts-Universität zu Kiel, Schwanenweg 20, D-24105 Kiel, Germany.
Sippell
Wolfgang G
WG
D000293:Adolescent; D002648:Child; D005260:Female; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D011629:Puberty, Precocious / Q000453:epidemiology / Q000209:etiology / Q000523:psychology / Q000628:therapy*; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000627:therapeutic use
D017329:Triptorelin Pamoate; D016729:Leuprolide